HUP0101343A2 - Antitest-citokin fúziós protein által közvetített immunválasz fokozása prosztaglandin-inhibitor együttes adagolásával - Google Patents

Antitest-citokin fúziós protein által közvetített immunválasz fokozása prosztaglandin-inhibitor együttes adagolásával

Info

Publication number
HUP0101343A2
HUP0101343A2 HU0101343A HUP0101343A HUP0101343A2 HU P0101343 A2 HUP0101343 A2 HU P0101343A2 HU 0101343 A HU0101343 A HU 0101343A HU P0101343 A HUP0101343 A HU P0101343A HU P0101343 A2 HUP0101343 A2 HU P0101343A2
Authority
HU
Hungary
Prior art keywords
immune response
prostaglandin inhibitor
antibody
enhancement
administration
Prior art date
Application number
HU0101343A
Other languages
English (en)
Inventor
Stephen D. Gillies
Original Assignee
Lexigen Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharmaceuticals Corporation filed Critical Lexigen Pharmaceuticals Corporation
Publication of HUP0101343A2 publication Critical patent/HUP0101343A2/hu
Publication of HUP0101343A3 publication Critical patent/HUP0101343A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

A találmány emlősben valamely előre megválasztott sejttípus ellenifokozott sejtölő immunválasz kiváltására alkalmas módszerekre éskészítményekre vonatkozik. A találmány szerinti módszerek éskészítmények valamely antitestcitokin immunkonjugátum és egyprosztaglandin-inhibitor kombinációján alapul. Az emlősnek adagoltimmunkonjugátum az előre megválasztott sejttípus ellen, így példáulráksejt ellen olyan immunválaszt vált ki, amely az önmagában azimmunkonjugátum által kiváltott immunválaszhoz képest fokozottimmunválasz elérését eredményezi a prosztaglandininhibitorimmunfokozása következtében. A találmány szerinti módszerek éskészítmények különösen alkalmasak emlősben szolid tumorok és vírusfertőzött sejtek elpusztítására. Ó
HU0101343A 1998-04-17 1999-04-16 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor HUP0101343A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8216698P 1998-04-17 1998-04-17
PCT/US1999/008376 WO1999053958A2 (en) 1998-04-17 1999-04-16 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor

Publications (2)

Publication Number Publication Date
HUP0101343A2 true HUP0101343A2 (hu) 2001-08-28
HUP0101343A3 HUP0101343A3 (en) 2003-10-28

Family

ID=22169464

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101343A HUP0101343A3 (en) 1998-04-17 1999-04-16 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor

Country Status (16)

Country Link
US (1) US20040033210A1 (hu)
EP (1) EP1071469A2 (hu)
JP (1) JP2002512204A (hu)
CN (1) CN1305387A (hu)
AU (1) AU758851B2 (hu)
BR (1) BR9909677A (hu)
CA (1) CA2328081A1 (hu)
CZ (1) CZ20003817A3 (hu)
HK (1) HK1038881A1 (hu)
HU (1) HUP0101343A3 (hu)
MX (1) MXPA00010151A (hu)
NO (1) NO20005186L (hu)
PL (1) PL343486A1 (hu)
RU (1) RU2217168C2 (hu)
WO (1) WO1999053958A2 (hu)
ZA (1) ZA200005477B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029732A2 (en) 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
DE69931908T2 (de) * 1998-04-15 2007-01-11 Lexigen Pharmaceuticals Corp., Lexington Steigerung der antikörper-zytokin-fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
CN100422332C (zh) * 1998-08-25 2008-10-01 默克专利股份公司 表达以及分泌制管张素和endostatin的免疫融合物
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU6227400A (en) * 1999-07-26 2001-02-13 Childrens Hospital Los Angeles Research Institute Fenretinide increases antibody cellular toxicity
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1252192B1 (en) 2000-02-11 2006-08-16 MERCK PATENT GmbH Enhancing the circulating half-life of antibody-based fusion proteins
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) * 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
CN104630129A (zh) * 2002-03-15 2015-05-20 北卡罗来纳大学查伯山分校 原肝干细胞和近肝干细胞
CA2510180C (en) * 2002-12-17 2012-09-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
EP1699822B1 (en) 2003-12-30 2008-04-23 MERCK PATENT GmbH Il-7 fusion proteins with antibody portions, their preparation and their use
ES2387028T3 (es) * 2003-12-31 2012-09-12 Merck Patent Gmbh Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
PL1706428T3 (pl) 2004-01-22 2010-02-26 Merck Patent Gmbh Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CN101072793B (zh) * 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EA016429B1 (ru) 2005-12-30 2012-04-30 Мерк Патент Гмбх Антитела против cd19 с пониженной иммуногенностью
ATE555125T1 (de) * 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
DE3812605A1 (de) * 1988-04-15 1990-06-07 Leskovar Peter Dipl Ing Dr Hab Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
AU660297B2 (en) * 1990-11-09 1995-06-22 Stephen D. Gillies Cytokine immunoconjugates
DK0706799T3 (da) * 1994-09-16 2002-02-25 Merck Patent Gmbh Immunkonjugater II
IL127739A0 (en) * 1996-07-02 1999-10-28 Bar Illan University Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases

Also Published As

Publication number Publication date
HK1038881A1 (zh) 2002-04-04
MXPA00010151A (es) 2002-08-06
US20040033210A1 (en) 2004-02-19
CA2328081A1 (en) 1999-10-28
NO20005186D0 (no) 2000-10-16
AU758851B2 (en) 2003-04-03
ZA200005477B (en) 2001-11-20
HUP0101343A3 (en) 2003-10-28
WO1999053958A2 (en) 1999-10-28
JP2002512204A (ja) 2002-04-23
NO20005186L (no) 2000-12-14
AU3566499A (en) 1999-11-08
PL343486A1 (en) 2001-08-27
WO1999053958A3 (en) 1999-12-02
EP1071469A2 (en) 2001-01-31
CN1305387A (zh) 2001-07-25
BR9909677A (pt) 2000-12-19
CZ20003817A3 (cs) 2002-08-14
RU2217168C2 (ru) 2003-11-27

Similar Documents

Publication Publication Date Title
HUP0101343A2 (hu) Antitest-citokin fúziós protein által közvetített immunválasz fokozása prosztaglandin-inhibitor együttes adagolásával
HUP0101352A2 (hu) Antitest-citokin fúziós protein által közvetített immunválasz fokozása angiogenézis-inhibitor együttes adagolásával
BR0112111A (pt) Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
PT758248E (pt) Formulacoes para o factor ix
EP1423107A4 (en) FATTY ALCOHOL DRUG CONJUGATES
HUP0204475A2 (en) Enhancing the circulating half-life of antibody-based fusion proteins
NO331072B1 (no) Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.
DE69427127T2 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
DE60017141D1 (de) Replikationskompetente anti-tumor vektoren
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
DE69230798T2 (de) Rekombinante immuntoxine
WO2004031230A3 (en) Novel mhc ii associated peptides
DE60238435D1 (de) Gezielte thrombose durch gewebefaktor polypeptiden
IT1270618B (it) Proteine ad attivita' antitumorale
EP1364657A4 (en) REMEDIES AGAINST TUMORS AFFECTING HEMATOPOIETIC BODIES
TR200101141T2 (tr) Antitümör etkiyi haiz antijenik proteini şifreleyen bir DNA'ya mahsus parçalar ihtiva eden farmasötik bileşim
WO2023159136A3 (en) Epitope engineering of cell-surface receptors
DE69534753D1 (de) Nierenpolycystose-gen
FI961584A0 (fi) C-reaktiivisista proteiinifragmenteista johdetut oligopeptidit
ATE431742T1 (de) Modifizierte zytokine für krebs therapie
WO2024077118A3 (en) Multispecific proteins and related methods
Pekkola-Heino Radiation response of squamous cell carcinoma: In vitro studies with cell lines in a 96-well plate clonogenic assay.
IT1254452B (it) N-ossidi ed n,n'-diossidi di 3-(piperazin-1-il)-propan-1,2-dioli
SE9901548D0 (sv) Helicobacter pylori antigens

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees